Digitalis Today: From Doctrine to Disrepute to Disciplined Reconsideration.

Area of Science:

• Cardiovascular Therapeutics
• Pharmacology
• Heart Failure Management

Background:

• Cardiac glycosides, once foundational heart failure therapy, fell into disuse due to toxicity concerns and lack of mortality benefit shown in the DIG trial.
• Toxicity was often linked to excessive serum concentrations, particularly in women, leading to therapeutic disrepute.

Purpose of the Study:

• To reassess the role of low-dose digitalis glycosides in contemporary cardiovascular therapeutics.
• To evaluate the safety and efficacy of digitalis therapy in selected heart failure patients with persistent residual risk.

Main Methods:

• Review of recent randomized trials (DIGIT-HF, DECISION) and a contemporary meta-analysis.
• Analysis of outcomes related to low-dose digitalis therapy with controlled serum concentrations.

Main Results:

• Consistent directional reductions in worsening heart failure events were observed with low-dose digitalis.
• No excess mortality was found when serum concentrations were carefully controlled.
• Findings suggest historical toxicity was related to excessive exposure, not intrinsic hazard.

Conclusions:

• Digitalis glycosides are not mortality-reducing foundational therapy but serve as complementary agents.
• Recommended for selected patients with persistent heart failure despite optimized therapy, especially those with recurrent decompensation or atrial fibrillation.